STAGE IVA PROSTATE CANCER AJCC V8

This study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the comb…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…

This study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…

This study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…

This study compares two different hormone therapy combinations (leuprolide plus abiraterone vs. relugolix plus abiraterone) in men with advanced prostate cancer who are also receiving radiation therapy. The goal is to see which combination causes less damage to the heart and bloo…

This study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers…

This phase III trial tests whether high-dose vitamin D can prevent bone loss in older men with prostate cancer who are receiving hormone therapy (ADT). The study will enroll 240 men aged 50 and older, giving them either high-dose vitamin D or a placebo for one year. Researchers w…

This phase 3 trial is testing whether adding surgery to remove the prostate or radiation therapy to standard drug treatment helps people with prostate cancer that has spread to other parts of the body. About 1,273 participants will receive either standard therapy alone or standar…

This study tests whether a combined PET/MRI scan using a radioactive tracer can accurately detect if prostate cancer has spread to nearby lymph nodes. Fifty men with high-risk localized prostate cancer will receive the scan before their planned prostate removal surgery. The resul…

This study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…

This study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…